rs12321461 (ATP2B1): Triglyceride SSRI interaction
Upload your raw genetic data once, we'll show you which variants you carry and what the research says.
Key takeaways
- - Triglyceride levels rise with the C allele
- - SSRI medication effect is linked to the C allele
- - Schizophrenia risk increases with the C allele
Key takeaways
- Triglyceride levels rise with the C allele
- SSRI medication effect is linked to the C allele
- Schizophrenia risk increases with the C allele
What the research says This variant is associated with higher triglyceride levels and increased SSRI medication levels in schizophrenia or bipolar disorder PMID 33824429. The effect size is 3.27 p=1e-6 in about 181 individuals with the risk allele C.
Reported associations Triglyceride levels this variant raises triglyceride levels with a reported effect size of 3.27 p=1e-6 sample 181 individuals risk/effect allele C PMID 33824429. SSRI levels this variant is linked to higher SSRI medication levels with a reported effect size of 3.27 p=1e-6 sample 181 individuals risk/effect allele C [PMID 33824429].
Evidence quality The supplied studies do not report a direct trait association for this variant; the rsid appears via GWAS catalog association. The evidence is limited to a single case-control study with 181 participants and a p-value of 1e-6.
Last lifestyle considerations on file for this variant.
Frequently asked questions
What does rs12321461 do?
rs12321461 is a genetic variant that raises triglyceride levels and may increase SSRI medication levels in people with schizophrenia or bipolar disorder.
Is this SNP linked to brain function?
The study does not report any direct link between rs12321461 and brain function beyond the observed association with triglycerides and SSRI levels.
Can I change my risk?
No, this is a descriptive finding; it does not indicate that changing lifestyle will alter your genetic risk.